Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Enzymatica AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -98.83%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Enzymatica AB's 3-Year ROIIC % or its related term are showing as below:
FRA:EN9's 3-Year ROIIC % is ranked worse than 90.91% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs FRA:EN9: -98.83
Enzymatica AB (FRA:EN9) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Enzymatica AB 3-Year ROIIC % Related Terms
Enzymatica AB 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Enzymatica AB's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzymatica AB 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Enzymatica AB's 3-Year ROIIC % falls into.
Enzymatica AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -4.72 (Dec. 2025) - -6.1969335 (Dec. 2022) )
/
( 9.198 (Dec. 2025) - 10.647 (Dec. 2022) )
=
1.4769335
/
-1.449
=
-101.93%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Enzymatica AB (FRA:EN9) has a 3-Year ROIIC % of -98.83 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Enzymatica AB and its competitors. According to the industry distribution chart, Enzymatica AB ranks #860 out of 946 companies in the Drug Manufacturers industry, placing it in the top 90.9%.
Is Enzymatica AB's 3-Year ROIIC % too high?
Enzymatica AB's current 3-Year ROIIC % is -98.83. Based on the distribution chart, Enzymatica AB ranks #860 out of 946 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enzymatica AB has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enzymatica AB ranks #860 out of 946 companies for 3-Year ROIIC %. This places Enzymatica AB in the lower half of its industry. The industry median 3-Year ROIIC % is 3.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Enzymatica AB and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enzymatica AB's current 3-Year ROIIC % is -98.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Fairly Valued. The stock's GF Value™ is €0.17, compared to a current price of €0.17 — trading 1.8% below its estimated fair value. The current 3-Year ROIIC % is -98.83. Enzymatica AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current 3-Year ROIIC % is -98.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enzymatica AB (FRA:EN9) Overvalued in 2026?
Based on GuruFocus' analysis, Enzymatica AB stock appears to be undervalued.
The current stock price of €0.17 is trading 1.8% below its estimated GF Value™ of €0.17.
GuruFocus considers Enzymatica AB to be Fairly Valued.
Key valuation signals for FRA:EN9:
3-Year ROIIC %: -98.83
GF Value™: €0.17 vs. price of €0.17 (1.8% below fair value)
No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
41GF Score
Get the complete analysis for FRA:EN9
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EN9 has been successfully added to your 
